The EU Court of Justice dismisses all appeals brought by a Danish pharmaceutical company and five generic manufacturers against the judgments of the General Court and upholds a decision of the Commission on patent settlement agreements between the companies (Lundbeck)

On 25 March 2021, the CJEU dismissed all the appeals brought by Danish pharmaceutical company H. Lundbeck A/S and five generic manufacturers against the judgments of the GCEU, thus upholding a decision of the EC on patent settlement agreements between Lundbeck and five generic manufacturers (Case C-586/16 P, Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission, EU:C:2021:241; Case C-588/16 P, Generics (UK) v Commission, EU:C:2021:242; Case C-591/16 P, Lundbeck v Commission, EU:C:2020:428; Case C-601/16 P, Arrow Group and Arrow Generics v Commission, EU:C:2021:244; Case C-611/16 P, Xellia Pharmaceuticals and Alpharma v Commission, EU:C:2021:245; and Case C-614/16 P, Merck v Commission, EU:C:2021:246). The judgment is significant as regards the interpretation and application of